NAFLD到MAFLD/MASLD学术更名后流行病学和诊疗结局的变化

肝脏 ›› 2025, Vol. 30 ›› Issue (7): 900-903.

NAFLD到MAFLD/MASLD学术更名后流行病学和诊疗结局的变化

张粉娜, 张心怡, 吕贝贝, 孙荣荣, 赵婷婷, 贺娜

710077 陕西西安西安医学院第一附属医院(张粉娜,张心怡,吕贝贝,孙荣荣,赵婷婷,贺娜);710021 陕西西安西安医学院(张心怡,孙荣荣,赵婷婷)

收稿日期:2025-03-20 出版日期:2025-07-31 发布日期:2025-08-11
通讯作者: 贺娜,Email: ylhena@163.com
基金资助:
陕西基础科学(化学、生物学)研究院基础科学研究计划(22JHQ091);北京肝胆相照公益基金会人工肝专项基金(iGandanF-1082024-RGG043)

Received:2025-03-20 Online:2025-07-31 Published:2025-08-11

摘要/Abstract

摘要： 在对肝脏脂肪变性的认知持续深入的进程中,非酒精性脂肪肝(NAFLD)诊断的局限性日益凸显。与此同时,关于代谢相关脂肪性肝病(MAFLD)以及代谢功能障碍相关脂肪性肝病(MASLD)这两个新的学术命名,相关争议不断。基于此背景,本研究旨在对不同定义下的患者群体在临床方面的差异以及预后状况展开总结与比较,从而使医务工作者能够直观地领会脂肪性肝病学术命名的演变意义,并为实施个体精准化治疗提供参考依据。

张粉娜, 张心怡, 吕贝贝, 孙荣荣, 赵婷婷, 贺娜. NAFLD到MAFLD/MASLD学术更名后流行病学和诊疗结局的变化[J]. 肝脏, 2025, 30(7): 900-903.

/ 推荐

参考文献

[1] Ludwig J, Viggiano T R, McGill D B, et al. Nonalcoholic steatohepatitis: mayo clinic experiences with a hitherto unnamed disease[J]. Mayo Clin Proc, 1980, 55(7): 434-438.
[2] Yang A, Zhu X, Zhang L, et al. Transitioning from NAFLD to MAFLD and MASLD: consistent prevalence and risk factors in a Chinese cohort[J]. J Hepatol, 2024, 80(4): e154-e155.
[3] Song S J, Lai J C, Wong G L, et al. Can we use old NAFLD data under the new MASLD definition?[J]. J Hepatol, 2024, 80(2): e54-e56.
[4] Wang X, Wu S, Yuan X, et al. Metabolic dysfunction-associated fatty liver disease and mortality among Chinese adults: a prospective cohort study[J]. J Clin Endocrinol Metab, 2022, 107(2): e745-e755.
[5] Chen L, Tao X, Zeng M, et al. Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD[J]. J Hepatol, 2024, 80(2): e64-e66.
[6] Ayada I, van Kleef L A, Alferink L J M, et al. Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: focusing on the non-overlap groups[J]. Liver Int, 2022, 42(2): 277-287.
[7] Perazzo H, Pacheco A G, Griep R H. Changing from NAFLD through MAFLD to MASLD: similar prevalence and risk factors in a large Brazilian cohort[J]. J Hepatol, 2024, 80(2): e72-e74.
[8] Nakano M, Kawaguchi M, Kawaguchi T. Almost identical values of various non-invasive indexes for hepatic fibrosis and steatosis between NAFLD and MASLD in Asia[J]. J Hepatol, 2024, 80(4): e155-e157.
[9] 刘云霄, 郭峰, 牛丽娜, 等. 从非酒精性脂肪性肝病到代谢功能障碍相关脂肪性肝病——基于临床特征差异分析[J]. 中华肝脏病杂志, 2024, 32(4): 346-353.
[10] Yu C, Wang M, Zheng S, et al. Comparing the diagnostic criteria of MAFLD and NAFLD in the Chinese population: a population-based prospective cohort study[J]. J Clin Transl Hepatol, 2022, 10(1): 6-16.
[11] He L, Zheng W, Qiu K, et al. Changing from NAFLD to MASLD: the new definition can more accurately identify individuals at higher risk for diabetes[J]. J Hepatol, 2024, 80(2): e85-e87.
[12] Kim D, Konyn P, Sandhu K K, et al. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States[J]. J Hepatol, 2021, 75(6): 1284-1291.
[13] Song R, Li Z, Zhang Y, et al. Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults[J]. Liver Int, 2024, 44(4): 1051-1060.
[14] Kim K S, Hong S, Ahn H Y, et al. Metabolic dysfunction-associated fatty liver disease and mortality: a population-based cohort study[J]. Diabetes Metab J, 2023, 47(2): 220-231.
[15] Moon J H, Kim W, Koo B K, et al. Metabolic dysfunction-associated fatty liver disease predicts long-term mortality and cardiovascular disease[J]. Gut Liver, 2022, 16(3): 433-442.
[16] Branković M, Dukić M, Gmizić T, et al. New therapeutic approaches for the treatment of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and increased cardiovascular risk[J]. Diagnostics (Basel), 2024, 14(2): 229.
[17] EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease[J]. Obes Facts, 2016, 9(2): 65-90.
[18] Cleveland E R, Ning H, Vos M B, et al. Low awareness of nonalcoholic fatty liver disease in a population-based cohort sample: the CARDIA study[J]. J Gen Intern Med, 2019, 34(12): 2772-2778.
[19] Wieland A C, Mettler P, McDermott M T, et al. Low awareness of nonalcoholic fatty liver disease among patients at high metabolic risk[J]. J Clin Gastroenterol, 2015, 49(1): e6-e10.
[20] Rojas Á, Lara-Romero C, Muáoz-Hernández R, et al. Emerging pharmacological treatment options for MAFLD[J]. Ther Adv Endocrinol Metab, 2022, 13: 20420188221142452.